Advertisement
     Stock news arrow Stocks 

Main Menu
Stock news
Forex news
Forex Charts
Live Market News
Economic Calendar
Links
Forum
About
User Menu
My Favourites
Bookmark Us
 
 
Login Form





Lost Password?
No account yet? Register
StockTopsites.com
FXtopsites.com
TOP 100 INVESTING SITES
TOP 100 FINANCIAL SITES
TOP 100 FOREX SITES

FeedTheBull - Top Stock market and Finance Sites


ALL |0-9 |A |B |C |D |E |F |G |H |I |J |K |L |M |N |O |P |Q |R |S |T |U |V |W |X |Y |Z


Palatin Technologies, Inc - PTN
 
  


 
 

Yahoo! Finance: PTN News

Latest Financial News for PALATIN TECH INC

Yahoo! Finance

Yahoo! Finance: PTN Financial Blogs

Latest Financial Financial Blogs for PALATIN TECH INC

Yahoo! Finance

MSN Money News - PTN

News about Palatin Technologie Inc

PTN - News and Analysis from Seeking Alpha

'PTN' Tag RSS Syndication from SeekingAlpha.com

  • Palatin Technologies, Inc. F4Q08 (Qtr End 06/30/08) Call Transcript

    (Tue, 30 Sep 2008 17:55:28 -0400)

    Palatin Technologies, Inc. (PTN)

    F4Q08 Earnings Call


    Complete Story »

  • Biotech Day In Review: AstraZeneca Enters Two Partnerships Worth $800 Million

    (Thu, 01 Feb 2007 04:45:06 -0500)

    AstraZeneca (AZN) signed two drug development deals, both of which start small, but have the potential to become significant. The first was with a privately held British biotech called Argenta Discovery, which could be worth up to $500 million.

    The two companies will collaborate to develop better bronchodilators that treat chronic obstructive pulmonary disease, also called smoker?s lung. AstraZeneca will make a $21 million upfront payment to Argenta and underwrite research, which is currently in the pre-clinical stage, into LAMA and MABA drugs that could be once-daily therapies. Human trials are at least a year off. AstraZeneca rose 40 cents...

  • Earnings Schedule & Estimates for Wednesday, September 13, 2006

    (Wed, 13 Sep 2006 06:36:42 -0400)

    Aastrom Biosciences Inc. (ASTM)
    FQ4 2006 Revenue Estimate: $160.00K
    FQ4 2006 EPS Estimate: $-0.04
    FQ1 2007 Revenue Estimate: $240.00K
    FQ1 2007 EPS Estimate: $-0.04
    FQ3 2006 reported on 05/10/06
    EPS Estimate: -$0.04 ¦ EPS Actual: ($0.04)
    05/10/06 Close: $1.53 Change($): $0.03 Change(%): 2.0%
    05/11/06 Close: $1.41 Change($): ($0.12) Change(%): -8.5%


    Complete Story »

  • Palatin Tech: Developing a New Aphrodesiac? (PTN, KG)

    (Mon, 01 May 2006 04:22:13 -0400)

    David Phillips (10Q Detective) submits: Melanocortin receptors [MC] are involved in the control of endocrine, autonomic and central nervous system functions. To date, five MC receptors subtypes have been identified. Targeting MC family of receptors provides therapeutic opportunities to treat a variety of conditions and diseases, including sexual dysfunction, obesity, cachexia (extreme wasting, generally secondary to a chronic disease) and inflammation. The 10Q Detective believes that MC-based therapeutics is one of the fastest growing areas of pharmaceutical research and development.

    Palatin Technologies,...




Investor Clicks Financial Advertising
Investor Clicks Financial Advertising

News for Palatin Technologies, Inc. - Google Finance

News for Palatin Technologies, Inc. - Google Finance

News for Palatin Technologies, Inc. - Google Finance

MarketWatch.com - All MarketWatch News - PTN

MarketWatch, a leading publisher of business and financial news, offers users up-to-the minute news, investment tools, and subscription products.

MarketWatch.com - All MarketWatch News - PTN
  • Biotech Stocks: Wyeth gains; benchmarks make narrow moves

    (Thu, 27 Sep 2007 03:33:00 -0500)

    NEW YORK (MarketWatch) -- Drug shares rose in Thursday afternoon trading, and Wyeth traded higher after the company announced a new chief executive and an increase in the share buyback plan.

  • Drug and biotech shares rise, Palatin jumps on data

    (Thu, 27 Sep 2007 09:47:08 -0500)

    NEW YORK (MarketWatch) - Drug and biotech shares rose in Thursday morning trading, boosted by Forest Labs and Enzon Pharmaceuticals . Shares of Palatin Technologies Inc. jumped 10% after the company announced results from an at-home Phase II trial evaluating bremelanotide for the treatment of female sexual arousal disorder. The Amex Pharmaceutical Index was up fractionally at 347.80, while the Amex Biotechnology Index rose to 825.84.

  • Movers & Shakers: Thursday's biggest stock gainers and decliners

    (Thu, 30 Aug 2007 04:50:00 -0500)

    Thursday's biggest stock gainers and decliners

  • Biotech Stocks: Palatin plunges on drug setback; Atherogenics continues rally

    (Thu, 30 Aug 2007 01:42:00 -0500)

    BOSTON (MarketWatch) -- Biotech stocks traded generally higher Thursday, but shares of Palatin Technologies plunged more than 60% in reaction to plans to delay Phase III testing for a prospective erectile-dysfunction drug over safety concerns voiced by regulators.

  • King Pharma, Palatin to delay ED candidate's Phase III testing

    (Thu, 30 Aug 2007 08:53:00 -0500)

    BOSTON (MarketWatch) -- King Pharmaceuticals and Palatin Technologies have delayed the launch of Phase III testing for an erectile-dysfunction drug candidate as a result of regulatory concerns, the said Thursday.

  • Palatin Tech, King Pharmaceutical Delay Phase III Bremelanotide Trial

    (Thu, 30 Aug 2007 08:22:00 -0500)

    Palatin Technologies Inc. and King Pharmaceuticals Inc. delayed plans for Phase III clinical trials of bremelanotide, which treats male erectile dysfunction. The decision follows comment from the Food and Drug Administration, which raised concerns about the acceptable benefit/risk ratio to support the progression of the program into Phase III studies. After reviewing the data generated in the Phase I and Phase II studies, the FDA questioned the overall efficacy results and the clinical benefit of the product, and cited blood pressure increases as its greatest safety concern. Palatin and King plan to review the FDA comments to determine...

  • King, Palatin trial delay due to FDA concerns

    (Thu, 30 Aug 2007 08:10:17 -0500)

  • King, Palatin delay erectile drug phase-III trial

    (Thu, 30 Aug 2007 08:09:58 -0500)

  • Biotech Stocks: Drug stocks gain, Bristol-Myers climbs on takeover talk

    (Wed, 31 Jan 2007 04:20:00 -0500)

    BOSTON (MarketWatch) -- Drug stocks closed higher Wednesday as shares of Bristol-Myers Squibb Co. gained on reports that the company has hired three leading banks to advise it on a possible takeover bid.

  • Palatin Tech to place 11 units at $2.44 each

    (Wed, 12 Apr 2006 07:51:27 -0500)

    NEW YORK (MarketWatch) - Palatin Technologies Inc. said Wednesday it signed an agreement to sell 11 million units at $2.44 each for a total of about $27 million. The Cranbury, N.J., biopharmaceutical company said each unit will comprise one common share share and one warrant to purchase 0.30 share of common stock at $2.44 a unit. The warrants have a five-year term and an exercise price of $2.88 a share. Shares of Palatin closed Tuesday at $2.35.



Add as favourites (0) | Quote this article on your site

Be first to comment this article

Only registered users can write comments.
Please login or register.

PTN 




Reddit!Del.icio.us!Google!Facebook!Slashdot!Netscape!Technorati!StumbleUpon!Newsvine!Furl!Yahoo!Ma.gnolia!Free social bookmarking plugins and extensions for Joomla! websites!
 

The Financial Ad Trader
The Financial Ad Trader - banner exchange
Member Of Candlestick Shop Banner Exchange

Stock Market Quotes
Starting...
Stock Market News
Popular Stocks
Random Stocks